SecBot SecBot
8-K ·Filed Feb 25, 2026

IRWD

IRONWOOD PHARMACEUTICALS INC
BEARISH
Impact 5/10
Horizonweeks Processed8mo ago SEC0001104659-26-019405
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

Despite management's optimistic guidance for 2026, the significant revenue decline in 2025 suggests ongoing pricing pressures that may be difficult to overcome. Traders should monitor whether the company can achieve its ambitious 2026 EBITDA target of over $300 million given the revenue headwinds. The increased cash position provides some buffer, but the fundamental trend remains negative.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$3.36
T+0 close · Feb 25, 2026 · via day close
Latest settled
+16.67%
T+60 · $3.92
Vs SPY
+9.72%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 25 $3.36entry
  2. T+1 · 9mo ago +8.93%α +9.47% · $3.66
  3. T+5 · 9mo ago +11.31%α +12.41% · $3.74
  4. T+20 · 8mo ago −5.06%α +0.18% · $3.19
  5. T+60 · 6mo ago +16.67%α +9.72% · $3.92
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ironwood Pharmaceuticals reported full-year 2025 revenue of $296 million, down from $351.4 million in 2024, with GAAP net income of $24 million and adjusted EBITDA of $138 million. Despite declining revenue and profits, the company reiterated strong 2026 guidance with expected total revenue of $450-$475 million and adjusted EBITDA exceeding $300 million, driven by improved net pricing and continued expense discipline. LINZESS demand grew 11% year-over-year in 2025.

Key Financial Metrics

Revenue
$296.2M
-15.7% YoY
Adj. EPS
$0.25
GAAP: $0.15
Guidance
$450M-$475M
maintained

Key Facts

  • Full-year 2025 revenue was $296.2 million, down 15.7% from $351.4 million in 2024
  • GAAP net income was $24 million in 2025, up from $0.9 million in 2024, but driven by one-time factors
  • Adjusted EBITDA was $138.1 million in 2025, up slightly from $129.4 million in 2024
  • LINZESS U.S. net sales declined 6% to $864.5 million in 2025
  • Company reiterates 2026 guidance of $450-$475 million revenue and >$300 million adjusted EBITDA
  • Cash and cash equivalents increased to $215.5 million from $88.6 million in 2024

Financial Impact

Revenue decreased by $55.3 million (15.7%) year-over-year, with LINZESS U.S. net sales down 6%

revenueepsebitdacashFlow

Segment Breakdown

SegmentRevenueGrowth
LINZESS$864.5M-5.6%

Risk Factors

  • Continued pricing pressure on LINZESS from Medicare Part D redesign
  • Failure to achieve 2026 guidance targets despite reiteration
  • Dependence on successful development of apraglutide to drive future growth

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-019405
Document: tm267094d1_8k.htm0001104659-26-019405
Document: 0001104659-26-019405-index-headers.html0001104659-26-019405
Document: 0001104659-26-019405-index.html0001104659-26-019405
Document: 0001104659-26-019405.txt0001104659-26-019405

Track record

13 reports on IRWD

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +20.35% at T+5 after the Nov 5, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $4.88 Now $4.85 −0.51% settles Dec 15
  2. Nov 13, 20263d ago 144 Neutral 2/10 Entry $4.84 Now $4.85 +0.21% settles Dec 15
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $4.81 Now $4.85 +0.83% settles Dec 9
  4. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $4.81 Now $4.85 +0.83% settles Dec 9
  5. Nov 5, 202611d ago 8-K Bullish 6/10 Entry $4.03 Now $4.85 +20.35% settles Dec 4
  6. Oct 28, 202619d ago SC 13G/A Neutral 3/10 Entry $3.61 Now $4.85 +34.35% settles Nov 25
  7. Oct 16, 20264w ago 8-K Neutral 3/10 Entry $3.50 to $4.85 Now $4.85 +38.57% ▲ +38.57% +39.73% vs SPY
  8. Aug 6, 202614w ago 8-K Bullish 7/10 Entry $4.26 to $4.29 Now $4.85 +13.85% ▲ +0.70% +0.10% vs SPY
  9. May 13, 202626w ago 8-K Mixed 6/10 Entry $3.68 to $3.63 Now $4.85 +31.79% ▼ −1.36% −0.75% vs SPY
  10. May 7, 202627w ago 8-K Bullish 7/10 Entry $4.17 to $3.24 Now $4.85 +16.31% ▼ −22.30% −25.44% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 53m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 25, 2026